Hot Picks: Biotech picks target cystic fibrosis trials and rare-disease drugs [BNN Bloomberg (Canada)]
Sionna Therapeutics, Inc. (SION)
Company Research
Source: BNN Bloomberg
BNN Bloomberg spoke with Ritu Baral, managing director covering health care and biotechnology at T-D Cowen, about three biotech companies she believes could see significant upside as drug development data and regulatory catalysts unfold. Key Takeaways New experimental cystic fibrosis therapies aim to target the underlying CFTR mutation, potentially improving outcomes for patients who do not reach normal function with current treatments. Mid-stage clinical trial data expected this year could determine whether new drug approaches significantly improve performance compared with existing standard-of-care therapies. Biotech companies entering product cycles after successful late-stage trial results often shift investor focus from scientific risk to commercial potential. Regulatory engagement remains critical as drug developers navigate staffing challenges and shifting dynamics within the U.S. Food and Drug Administration. Positive late-stage clinical results in rare-disease th
Show less
Read more
Impact Snapshot
Event Time:
SION
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SION alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SION alerts
High impacting Sionna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SION
News
- Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? [Yahoo! Finance]Yahoo! Finance
- This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares [Yahoo! Finance]Yahoo! Finance
- Sionna Therapeutics (SION) had its "buy" rating reaffirmed by UBS Group AG.MarketBeat
- Sionna Therapeutics (SION) had its "buy" rating reaffirmed by Guggenheim.MarketBeat
- Sionna Therapeutics (SION) had its "buy" rating reaffirmed by BTIG Research. They now have a $58.00 price target on the stock.MarketBeat
SION
Earnings
- 11/5/25 - Beat
SION
Sec Filings
- 3/6/26 - Form 4
- 3/5/26 - Form 144
- 3/2/26 - Form S-8
- SION's page on the SEC website